Davis Polk advised Solazyme, Inc. on its SEC-registered initial public offering of 12,621,250 shares of common stock for an aggregate price to the public of approximately $227 million. Solazyme sold 12,021,250 shares, including 1,646,250 shares sold by Solazyme pursuant to an over-allotment option granted to the underwriters, and certain selling stockholders sold 600,000 shares. Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. were the joint book-running managers. The shares are listed on the Nasdaq Global Select Market under the symbol “SZYM.”

Headquartered in South San Francisco, Solazyme, Inc. is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value tailored oils. Solazyme’s renewable products can replace or enhance oils derived from the world’s three existing sources – petroleum, plants and animal fats. Solazyme is focused on commercializing its products into three target markets: (1) fuels and chemicals, (2) nutrition and (3) skin and personal care. Solazyme’s oils and fuels provide compelling solutions to increasingly complex issues of fuel scarcity, energy security and environmental impact while fitting into the pre-existing multi-trillion dollar fuel infrastructure.

The Davis Polk team included partner Alan F. Denenberg and associates Beth Hooton Ruiz and Tyler P. Pender. Associates Vishnu Reddy and Daniel J. Ray provided intellectual property advice. Counsel Loyti Cheng and associate Adam Riedel provided environmental advice. Counsel Cynthia Akard provided benefits advice. Partner Rachel D. Kleinberg and associate M. Ryan LaRosa provided tax advice. Associate Catherine L. Martin provided Investment Company Act advice. Kimberly Kakade was the legal assistant on the transaction. Members of the Davis Polk team are based in the Menlo Park and New York offices.